Bessemer Group Inc. Buys 32,331 Shares of Prestige Consumer Healthcare Inc. $PBH

Bessemer Group Inc. increased its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 11.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 309,931 shares of the company’s stock after acquiring an additional 32,331 shares during the quarter. Bessemer Group Inc.’s holdings in Prestige Consumer Healthcare were worth $19,121,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Profund Advisors LLC raised its position in shares of Prestige Consumer Healthcare by 3.2% in the 3rd quarter. Profund Advisors LLC now owns 6,770 shares of the company’s stock valued at $422,000 after purchasing an additional 207 shares during the last quarter. Cerity Partners LLC raised its position in shares of Prestige Consumer Healthcare by 5.9% in the 2nd quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock valued at $310,000 after purchasing an additional 218 shares during the last quarter. Diversify Advisory Services LLC raised its position in shares of Prestige Consumer Healthcare by 4.6% in the 3rd quarter. Diversify Advisory Services LLC now owns 5,837 shares of the company’s stock valued at $354,000 after purchasing an additional 256 shares during the last quarter. Geneos Wealth Management Inc. raised its position in shares of Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after purchasing an additional 269 shares during the last quarter. Finally, Barrow Hanley Mewhinney & Strauss LLC raised its position in shares of Prestige Consumer Healthcare by 106.8% in the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after purchasing an additional 283 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

PBH opened at $46.69 on Friday. Prestige Consumer Healthcare Inc. has a 12-month low of $42.62 and a 12-month high of $89.37. The company has a current ratio of 3.57, a quick ratio of 1.93 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $2.21 billion, a PE ratio of 11.94, a P/E/G ratio of 1.50 and a beta of 0.40. The firm has a 50 day moving average of $57.87 and a two-hundred day moving average of $61.38.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The company had revenue of $281.62 million during the quarter, compared to analyst estimates of $293.64 million. During the same period in the previous year, the firm posted $1.32 earnings per share. The company’s revenue was down 5.0% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.43 EPS for the current year.

Prestige Consumer Healthcare News Summary

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Negative Sentiment: Prestige reported fiscal Q4 earnings and revenue below expectations, with EPS of $1.23 versus the $1.39 consensus and revenue of $281.6 million versus $292.0 million expected, raising concerns about slower sales momentum and earnings execution. Prestige Consumer Healthcare: Fiscal Q4 Earnings Snapshot
• Negative Sentiment: Several law firms announced securities-fraud investigations into Prestige Consumer Healthcare following the earnings release, which can add overhang and increase investor anxiety around possible disclosure issues. Securities Fraud Investigation Into Prestige Consumer Healthcare (PBH) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
• Negative Sentiment: Canaccord Genuity cut its price target on PBH from $86 to $72, signaling a more cautious view on the company’s outlook even though it kept a Buy rating. Canaccord Genuity price target update
• Negative Sentiment: Oppenheimer downgraded Prestige Consumer Healthcare, adding to the negative analyst reaction after the earnings miss and reinforcing concerns about near-term performance. Oppenheimer downgrades Prestige Consumer Healthcare (PBH)
• Neutral Sentiment: The company’s earnings call and presentation may help investors assess whether management can defend margins and stabilize growth after the weak quarter. Prestige Consumer Healthcare Inc. (PBH) Q4 2026 Earnings Call Transcript

Insider Activity

In related news, VP Jeffrey Zerillo sold 1,207 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the transaction, the vice president directly owned 42,820 shares in the company, valued at $2,354,671.80. The trade was a 2.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently commented on PBH shares. Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday. Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday. Jefferies Financial Group reduced their price target on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Finally, Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a research report on Thursday. Two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $70.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).